Study guide
11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis
Key Takeaways Explain This Topic AI
Gout results from monosodium urate crystal deposition in articular and periarticular tissues; classic presentation is an acute explosive monoarthritis reaching maximum intensity within 6–24 hours, involving the first metatarsophalangeal joint (podagra) in over 70% of initial attacks; synovial fluid analysis under polarised light microscopy confirms needle-shaped, strongly negatively birefringent crystals.
NICE NG219 offers an NSAID, colchicine (maximum 6 mg per course) or a short course of oral corticosteroid as first-line treatment for a gout flare, with intra-articular or intramuscular steroid if these are unsuitable; existing allopurinol is continued through a flare.
Urate-lowering therapy (allopurinol or febuxostat; allopurinol if major CVD) is offered for multiple or troublesome flares, CKD 3–5, diuretic use, tophi or chronic gouty arthritis, usually started 2–4 weeks after a flare and titrated to urate below 360 µmol/L (300 if tophi).
Pseudogout (calcium pyrophosphate dihydrate / CPPD deposition disease) predominantly affects older adults, presenting as acute monoarthritis of large joints (knee #1 in > 50%, wrist); plain radiographs reveal chondrocalcinosis (linear cartilage calcification), and polarised light microscopy demonstrates rhomboid-shaped, weakly positively birefringent crystals.
Septic arthritis is an orthopaedic emergency most commonly caused by Staphylococcus aureus; urgent synovial fluid aspiration for microscopy, Gram stain, and culture must be performed BEFORE starting empirical high-dose intravenous flucloxacillin (2 g QDS), followed by immediate orthopaedic surgical joint washout and debridement to prevent irreversible articular cartilage necrosis within 24–48 hours.
Last updated: October 2026
Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis
An acutely painful, red, hot, swollen joint is one of the most critical presentations in acute medicine and rheumatology. Differentiating rapidly between crystal-induced synovitis and bacterial joint sepsis is paramount: while crystal arthropathies respond promptly to targeted medical anti-inflammatory therapies, delayed drainage and delayed antibiotic therapy in septic arthritis causes permanent chondrocyte death and irreversible joint destruction within 24 to 48 hours.
Gout (Monosodium Urate Arthropathy)
Gout is a metabolic disorder characterized by the precipitation and deposition of monosodium urate (MSU) monohydrate crystals within synovial joints and surrounding soft tissues. Deposition occurs when serum urate concentrations exceed physiological solubility limits (approximately > 360 µmol/L or 6.8 mg/dL).
Pathophysiology
Uric acid is the end-product of endogenous and dietary purine degradation, catalyzed by the hepatic enzyme xanthine oxidase : Hypoxanthine → Xanthine Oxidase Xanthine → Xanthine Oxidase Uric Acid \text{Hypoxanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Xanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid} Hypoxanthine Xanthine Oxidase Xanthine Xanthine Oxidase Uric Acid
Hyperuricaemia arises from underexcretion of urate by the kidneys (~90% of cases) or overproduction of purines (~10%).
Phagocytosis of precipitated MSU crystals by synovial macrophages triggers the intracellular NLRP3 inflammasome , driving the cleavage and massive release of pro-inflammatory cytokines, predominantly interleukin-1 beta (IL-1β) . This promotes rapid neutrophil recruitment and intense acute synovitis.
Risk Factors & Secondary Triggers
Non-Modifiable: Male sex, advanced age, postmenopausal state in women, genetic polymorphisms in renal urate transporters (SLC2A9, ABCG2).
Modifiable / Dietary Excess: Excessive consumption of purine-dense foods (red meat, game, organ meats/offal, shellfish/seafood), high-fructose corn syrup beverages, and alcohol intake (especially beer , which contains both alcohol and absorbable purines/guanosine, and distilled spirits).
Comorbidities: Obesity, metabolic syndrome, hypertension, type 2 diabetes mellitus, chronic kidney disease (CKD) (reduced tubular urate clearance), and myeloproliferative/lymphoproliferative disorders (accelerated cell turnover).
Pharmacological Triggers:
Diuretics (Thiazide and Loop diuretics): Inhibit tubular urate secretion and increase reabsorption through volume contraction.
Low-dose aspirin (< 1 g daily; paradoxically blocks urate excretion, whereas high-dose is uricosuric).
Calcineurin inhibitors (ciclosporin, tacrolimus).
Cytotoxic chemotherapy (tumor lysis syndrome).
Clinical Presentation
Acute Gout Flare: Explosive, agonizing monoarthritis reaching maximal intensity within 6 to 24 hours . The joint is intensely erythematous, swollen, warm, and exquisitely tender (even the light pressure of a bedsheet or gentle breeze provokes excruciating pain). Periarticular erythema may mimic cellulitis.
Anatomical Predilection: The first metatarsophalangeal (MTP) joint is the site of involvement in over 70% of initial attacks (podagra) . Other frequent sites include the ankle, midfoot, knee, wrist, and olecranon bursa.
Chronic Tophaceous Gout: Untreated chronic hyperuricaemia leads to the formation of tophi : nodular, chalky aggregates of monosodium urate crystals surrounded by foreign-body giant cell granulomas. Tophi appear on the helix of the external ear , olecranon bursae, patellar tendons, Achilles tendons, and digit extensor surfaces. They can ulcerate, extruding a white, tooth-paste-like chalky paste.
Diagnostic Investigations
Synovial Fluid Arthrocentesis (Gold Standard): Polarised light microscopy with a first-order red compensator demonstrates:
Needle-shaped crystals with pointed ends.
Strongly negative birefringence: Crystals oriented parallel to the slow axis of the red compensator filter appear bright yellow , whereas crystals lying perpendicular turn blue .
Serum Uric Acid Warning: Serum urate concentrations can be paradoxically normal or low during an acute gout flare , because acute-phase systemic inflammation (IL-6 release) stimulates renal uricosuria. A normal serum uric acid level during a flare does NOT exclude gout . Definitive serum urate evaluation should be repeated 2 to 4 weeks after complete clinical resolution.
Plain Radiography: Early radiographs show only non-specific soft tissue swelling. In chronic tophaceous gout, radiographs characteristically demonstrate "punched-out" periarticular cortical bone erosions with sclerotic margins and overhanging bony edges ("rat-bite" or "Martel's" erosions), with joint space preservation until terminal stages.
Acute Flare Management
First-Line Options (NICE NG219, 2022): offer an NSAID, colchicine or a short course of oral corticosteroid , choosing according to comorbidities, co-prescriptions and preference:
Oral NSAIDs: for example naproxen 500 mg twice daily (or indometacin), with a proton pump inhibitor for gastroprotection.
Oral Colchicine: 500 micrograms two to four times daily until symptoms settle, to a maximum of 6 mg per course (do not repeat a course within 3 days; BNF). Colchicine inhibits microtubule polymerisation and neutrophil chemotaxis; its dose-limiting adverse effect is diarrhoea , with nausea and abdominal cramps. Reduce the dose or avoid it in renal impairment and with interacting drugs (clarithromycin, statins, ciclosporin).
Oral Prednisolone: for example 30–35 mg daily for 3–5 days , useful when NSAIDs and colchicine are unsuitable.
When First-Line Options Are Unsuitable: In patients with advanced chronic kidney disease , active peptic ulcer disease, heart failure or anticoagulation, NSAIDs are contraindicated and colchicine is risky (accumulation causes myopathy, neuropathy and bone marrow toxicity). Use oral prednisolone or an intra-articular (or intramuscular) corticosteroid injection (e.g. methylprednisolone 40–80 mg) once septic arthritis is excluded.
Urate-Lowering Therapy and Flares:
If the patient is already taking allopurinol or febuxostat when a flare occurs, continue it at the current dose and add acute treatment.
New ULT is usually started 2–4 weeks after a flare has settled , but NICE NG219 allows starting it during a flare if flares are frequent . Rapid falls in urate can mobilise crystals and trigger flares, so ULT always starts at a low dose with flare prophylaxis considered.
Long-Term Urate-Lowering Therapy (ULT)
Timing: Discuss ULT with everyone after their first flare; start it 2–4 weeks after a flare settles (or during a flare if flares are frequent).
Offer ULT (NICE NG219) to people with:
- multiple or troublesome flares
- chronic kidney disease (stages 3–5)
- diuretic therapy
- tophi
- chronic gouty arthritis
First-Line ULT: Allopurinol or Febuxostat (treat-to-target), chosen with the patient; offer allopurinol rather than febuxostat to people with major cardiovascular disease .
Allopurinol competitively inhibits xanthine oxidase . Start at 100 mg daily (50 mg daily in CKD stages 3–5) and increase in 100 mg steps about every 4 weeks, checking serum urate, until target (maximum 900 mg daily).
Febuxostat is a non-purine selective xanthine oxidase inhibitor (80–120 mg daily).
Target Serum Urate: below 360 µmol/L for everyone; consider below 300 µmol/L for people with tophi or chronic gouty arthritis , or continuing flares despite a urate below 360 µmol/L.
Flare Prophylaxis: Consider colchicine (500 micrograms once or twice daily) while ULT is started and titrated, usually for up to 6 months; a low-dose NSAID or low-dose prednisolone is an alternative if colchicine is unsuitable.
Pharmacogenomic Safety: Screen for the HLA-B*5801 allele prior to starting allopurinol in individuals of Han Chinese, Korean, or Thai ancestry. Presence of HLA-B*5801 confers a severe risk of life-threatening severe cutaneous adverse reactions ( SCAR / Stevens-Johnson syndrome / DRESS syndrome ).
Pseudogout (Calcium Pyrophosphate Dihydrate / CPPD Deposition)
Pseudogout (acute calcium pyrophosphate crystal arthritis) is caused by the precipitation of calcium pyrophosphate dihydrate (CPPD) crystals in articular fibrocartilage and hyaline cartilage, a condition termed chondrocalcinosis .
Risk Factors & Metabolic Associations
Advanced Age: Strongest predictor; prevalence exceeds 30% in individuals aged > 80 years.
Prior Joint Trauma: Previous meniscectomy or joint surgery.
Underlying Metabolic Disorders (Screening Workup):
Haemochromatosis: Iron overload (HFE gene; check ferritin and transferrin saturation). Characteristic involvement of the 2nd and 3rd MCP joints with hook-like osteophytes.
Primary Hyperparathyroidism: Hypercalcaemia driving pyrophosphate crystallization (check serum calcium, phosphate, and PTH).
Hypomagnesaemia: Low magnesium enhances pyrophosphate precipitation (check serum magnesium).
Hypophosphatasia and Wilson's disease.
Clinical Presentation & Joint Distribution
Typically presents as an acute monoarthritis or oligoarthritis.
Characteristically involves large joints : Knee (#1, > 50% of cases) , wrist, shoulder, ankle, and hip. First MTP joint involvement is distinctly rare.
Clinical symptoms mirror gout: acute pain, erythema, swelling, and joint effusion, though onset is often slightly more insidious than gout (taking 24–48 hours to peak).
Diagnostic Hallmarks
Polarised Light Microscopy:
Rhomboid-shaped or rectangular crystals with blunt ends.
Weakly positive birefringence: Crystals lying parallel to the slow axis of the red compensator filter appear pale blue , whereas crystals lying perpendicular turn yellow .
Plain Radiography: Pathognomonic chondrocalcinosis : fine, punctate, linear calcifications outlining the fibrocartilage (e.g., knee menisci, triangular fibrocartilage complex of the wrist, pubic symphysis) and hyaline articular cartilage.
Management
Joint aspiration (arthrocentesis) alone provides immediate pain relief by decompressing capsular tension.
Pharmacotherapy: Intra-articular corticosteroid injection; oral NSAIDs or low-dose colchicine. Unlike gout, there is no pharmacological agent available to dissolve intra-articular CPPD crystal deposits.
Septic Arthritis (The Acute Orthopaedic Emergency)
Septic arthritis is a closed-space bacterial infection of the synovial joint space. It is a true medical and surgical emergency: chondrocyte proteases and bacterial endotoxins trigger rapid, irreversible articular cartilage destruction and permanent joint dysfunction within 24 to 48 hours of onset.
Route of Infection & Microbiology
Pathogenesis: Haematogenous seeding of the richly vascularized synovial membrane (#1 route); direct percutaneous inoculation (penetrating trauma, arthrocentesis, intra-articular injection); or contiguous spread from adjacent osteomyelitis.
Microbial Pathogens:
Staphylococcus aureus (#1 cause overall, > 50% of adult cases): Including methicillin-resistant S. aureus (MRSA).
Streptococcus species (~20%): Streptococcus pyogenes (Group A strep), Streptococcus pneumoniae .
Neisseria gonorrhoeae: Young, sexually active adults. Manifests either as localized septic monoarthritis or Disseminated Gonococcal Infection (DGI: triad of migratory tenosynovitis, maculopapular/pustular skin lesions, and polyarthralgia followed by purulent monoarthritis).
Gram-Negative Bacilli (E. coli, Pseudomonas aeruginosa): Elderly, immunosuppressed, diabetes, or intravenous drug users (IVDUs; sternoclavicular and sacroiliac joint predilection).
Clinical Presentation
Acute, severe, monoarticular pain, swelling, and heat.
Exquisite limitation of both ACTIVE and PASSIVE joint movement in all planes.
Complete inability to bear weight on the affected limb.
Systemic upset: High-grade pyrexia (> 38.5°C), rigors, tachycardia, and diaphoresis (note: elderly, immunocompromised, and cirrhotic patients may be afebrile).
Most Commonly Affected Joint: Knee (~50% of cases) , followed by hip, shoulder, ankle, and wrist.
- MANDATORY URGENT CLINICAL PATHWAY Suspected Septic Joint (Red, Hot, Swollen, Immobile Joint)
- │
- ▼
- 1. EMERGENCY DIAGNOSTIC ARTHROCENTESIS (Synovial Fluid Aspiration)
- MUST be performed BEFORE any antimicrobial administration
- Send for urgent Microscopy, Gram Stain, Leukocyte Count, and Culture
- Send Blood Cultures (2 sets) simultaneously
- │
- ▼
- 2. IMMEDIATE EMPIRICAL INTRAVENOUS ANTIBIOTIC THERAPY
- Commenced IMMEDIATELY AFTER joint aspiration
- First-Line: IV Flucloxacillin 2 g QDS
- High MRSA Risk / Penicillin Allergy: IV Vancomycin
- Gonococcal / Gram-Negative Risk: Add IV Ceftriaxone 2 g daily
- │
- ▼
- 3. EMERGENCY ORTHOPAEDIC REFERRAL FOR SURGICAL JOINT WASHOUT
- Arthroscopic debridement or Open Arthrotomy in Theatre
- Evacuates purulent material, decompresses capsular pressure, halts necrosis
- Synovial Fluid Interpretation
Macroscopic Appearance: Turbid, cloudy, or frankly purulent (pus).
White Cell Count (WCC): Characteristically > 50,000 cells/µL (often > 100,000 cells/µL), with > 90% polymorphonuclear neutrophils .
Gram Stain: Positive in 50–70% of staphylococcal infections.
Culture: Yields definitive identification and antimicrobial sensitivities (prolonged culture required for gonococcus and fastidious organisms).
Comparison: Gout vs Pseudogout vs Septic Arthritis
Diagnostic Parameter Gout Pseudogout (CPPD) Septic Arthritis
Primary Crystal / Pathogen Monosodium Urate (MSU) Calcium Pyrophosphate Dihydrate (CPPD) Staphylococcus aureus (#1), Streptococcus , N. gonorrhoeae
Synovial Polarised Microscopy Needle-shaped; Strongly Negative birefringence (Yellow when parallel) Rhomboid-shaped; Weakly Positive birefringence (Blue when parallel) No crystals (unless co-existent); Gram-positive or negative bacteria
Synovial Leukocytes 2,000–50,000/µL (~70% neutrophils) 2,000–50,000/µL (~70% neutrophils) > 50,000–100,000/µL (> 90% neutrophils)
Synovial Appearance Turbid, white/yellow Turbid, serosanguinous/yellow Frankly purulent, cloudy pus
Characteristic Joint 1st MTP (Podagra, > 70%) , ankle, midfoot Knee (> 50%) , wrist, shoulder Knee (~50%) , hip, shoulder, ankle
Classic X-ray Features Punched-out erosions with sclerotic overhanging edges ('rat-bite') Chondrocalcinosis (linear cartilage calcification) Soft tissue swelling; late joint space destruction, periostitis
Systemic Features Low-grade fever possible Afebrile or mild pyrexia High pyrexia, rigors, tachycardia, toxic appearance
Acute Management Oral NSAID, colchicine, or prednisolone; continue existing ULT; new ULT usually after the flare settles Aspiration, Intra-articular Steroids, NSAIDs Urgent aspiration THEN Empirical IV Antibiotics + Emergency Surgical Washout
Long-Term Treatment Allopurinol or febuxostat to urate < 360 µmol/L (< 300 if tophi) ± colchicine prophylaxis Treat underlying metabolic cause (Fe, Ca, Mg) 4–6 weeks targeted antibiotics (IV stepdown to oral)